Background: Interstitial Lung Disease (ILD) associated to Connective Tissue Disease (CTD) represent a challenge for clinicians and researchers because of their significant morbidity and mortality. Although the different types of ILD associated to CTD are often studied and managed as one because of their autoimmune background, there are considerable differences in their etiopathogenesis and therefore it can be assumed that there are differences in their response to treatment (1). Even though previous studies have analyzed the impact of immunosupipression in ILD secondary to sclerodema, additional studies are needed in order to determine the response to treatment of the different forms of ILD associated to CTD (2-3).
Objectives: To characterize and analyze the response to treatment of different types of ILD associated to CTD. The primary endpoint is the Functional Vital Capacity (FVC) change at 6 months and 1 year, and secondary endpoints arere the change in Diffusion Capacity of the Lung for Carbon Monoxide and in a 6 Minute Walk Test. Methods: A prospective cohort study is being carried out where all patients who present to the Mayo Clinic Florida pulmonary clinic, age 18 to 80, with established CTD and diagnosed with ILD, and all patients with ILD who meet the criteria for immunologic mediated process, are being followed for a year in order to evaluate the clinical and functional outcomes to treatment. Patients with moderate to severe Pulmonary Hypertension, and active smokers with bronchiolitis pattern are being excluded. Exploratory analysis were performed on the first group of patients enrolled in the study, continuous variables were described with central tendency measures and the mean absolute difference in adjusted 12-month FVC was analyzed between the different types of CTDs using student's t test. Results: Thirteen patients with ILD were enrolled in the study's initial phase. Five of the patients had been diagnosed with an Inflammatory Myopathy (IM), 2 with Rheumatoid Arthritis, 1 with an Undifferentiated Connective Tissue Disease, 1 with Churg-Strauss Syndrome, and one with Systemic Sclerosis. One patient was treated with Rituximab only; 2 with Rituximab and a steroid; 3 with Mycophenolate Mofetil (MMF) only; 2 with steroids, MMF, and Rituximab; 1 with a TNF inhibitor and MMF; 1 with MMF and steroids; 1 with Azathioprine and steroids; and 1 received only steroids. IMs were compared to the rest. At 1 year follow-up FVC mean absolute difference for the IMs demonstrated and improvement of 0.43 while the other CTDs had worsen by a mean of 0.04 (p=0.01). There were no statistical differences at 6 months for all outcomes or at 1 year for DLCO and 6MWT. Conclusions: To our knowledge, this is the first time that a cohort of ILD associated to CTD patients is followed and analyzed after 1 year of treatment. Our results suggest that there is a difference in the response to treatment of ILD depending on the underlying CTD. Specific types of ILD associated to CTD likely benefit from early and aggressive treatment, but longer follow ups and larger studies are needed in order to be able to validate and further understand these pathologies. Results: A total of 692 patients were recruited, 608 women (87.9%). Seventy (70, 10.1%) patients were classified as seropositive and 75 (10.8%) as seronegative by Kasukawa's criteria. Sixty-two (62, 8.9%) patients were classified as seropositive and 54 (7.8%) as seronegative according to Alarcón-Segovia's criteria. There were no significant differences in age at disease onset, age at diagnosis or disease duration (p>0.05) between seropositive and seronegative patients. Seropositive patients with Kasukawa's criteria presented more frequently: lymphadenopathy, malar rash, leukopenia, Raynaud's phenomenon, muscle weakness and increase of muscle enzymes (Table 1) . By Alarcón-Segovia's criteria, patients who developed myositis were more frequent in the seropositive group (p=0.007, OR 3.25, 95% CI, 1.44-7.32). Background: Systemic sclerosis is an autoimmune disease characterized by microvascular damage and fibrosis. There are several studies that shown macrovascular damage with arterial stiffness (AS) and the risk of cardiovascular complications. Carotid-femoral pulse wave velocity (CF-PWV) and augmentation index (AIx) are two competent methods to determine AS and predictors of cardiovascular disease. Association between AS and microvascular damage is unknown in systemic sclerosis patients. Objectives: To determine the frequency of arterial stiffness in patients with systemic sclerosis and its association with clinical manifestations. Methods: We performed a cross-sectional study; patients with diagnosis of systemic sclerosis according to ACR/EULAR 2013 criteria were included and the control group was selected from a database of mechanical vascular service. AS was non-invasively assessed by Pulse pen device and AIx was evaluated by tonometry. Statistical analysis was done with SPSS v22 software, we calculated mean and standard deviation, for continuous variables we used Student t test, categorical variables were analyzed by using chi-square or Fisher's exact test. The correlation of AS and clinical variables was assessed with Spearman's correlation. Results: Forty seven patients were included and compared with 39 healthy subjects; mean age of study group was 48±14. vs control group 47±13.7 (p=0.08) 93% were female. Prevalence of AS was 11% vs 3% p=0.039. AS was more frequent in limited systemic sclerosis sub-group and we found correlation with abnormal capillaroscopy, Rho 0.292 p=0.04. Conclusions: Arterial stiffness is more prevalent in patients with limited systemic sclerosis and association with abnormal caillaroscopy suggest that both macro and microvascular damage is present in these patients and could explain the presence of early atherosclerosis and increased risk of cardiovascular disease. Background: Systemic sclerosis (Ssc) is a chronic inflammatory autoimmune disease, that involves various tissues and organs, including the cardiovascular system. Ssc patients might suffer from a number of complications -including cardiovascular system diseases. Diagnostic imaging is an important tool in assessment of vascular lesions, and ultrasound (including Doppler ultrasound) is one of the most important examinations, which allow to scan for presence of atherotic lesions, assess the intima-media complex thickness as well as provide measurements of the blood flow parameters. Objectives: The aim of study was to determine if there is any difference in the intima-media complex thickness as well as in blood flow parameters measured using Doppler ultrasound examination in scleroderma patients and the general population. Methods: 35 patients, aged 19-75, with diagnosed systemic scleroderma were examined using a Doppler ultrasound examination. Thickness of intima-media complex (IMT) approximately 2 centimeters from the carotid bulb was assessed for both right and left common carotid artery (CCA). The standard parameters of blood flow were measured -including peak systolic velocity (PSV), end diastolic velocity (EDV), as well as resistive index (RI), pulsative index (PI) and standard deviation (SD) was measured in the common carotid arteries, internal carotid arteries (ICA) as well as in the vertebral arteries (VA). A positive correlation between the age of examined subjects and the IMT was found (p=0.002; R=0.49). Additionaly, a negative correlation between the IMT and the EDV was found (p=0.008, R=-0.44).
Conclusions:
The mean thickness of intima-media complex in the examined group of SSc patients is within the values that were established for a healthy population, however a further investigation, including a control group study will allow to evaluate whether there is no correlation between systemic sclerosis and increased IMT. A negative correlation between IMT and EDV was shown, which is an interesting finding, and could be confirmed in a control group study and on a larger group of patiens. Background: The association between cancer and autoimmune myositis is well established and has lead to the common practice of malignancy screening in asymptomatic individuals. The international literature advocates widely for cancer screening in autoimmune myositis however no consensus or guideline has been published to set forth a process for screening standardisation (1). Malignancy screening is a complicated topic and recommendations in favour of screening should in principle be based on a judicious assessment of the evidence in terms of the benefits, risks and costs. In inflammatory myositis there is currently insufficient evidence to support any recommendation with respect to cancer screening. In the absence of clinical guideline and quality evidence, our study aimed to establish the current trends in malignancy screening amongst Australian Rheumatologists. Objectives: To explore the current trends in malignancy screening in autoimmune myositis amongst Australian Rheumatologists using an online questionnaire. Methods: Research approval was granted by The Townsville Hospital. An invitation email containing the survey weblink was sent twice to 386 Australian Rheumatologists between August 2015 and August 2016. Voluntary participation and anonymity were guaranteed. The questionnaire contained a fixed set of multiple choice questions that requested data on respondent demographics, practice setting and screening preference, practice and concerns. Open entry comment was an option throughout the questionnaire. Fifty-eight Rheumatologists, 1 Immunologist and 1 Paediatric Rheumatologist responded (16% response rate). There were 3 survey dropouts. The data was pooled, coded and analysed using statistical software. All data was included in the analysis. Results: Most respondents (N=58) were in private (67%) and/or public practice (68%), in practice for >10 years (70%), conducted cancer screening (93%) and were "very" or "somewhat" confident in their screening practice (90%). The majority (72%) performed cancer screening independent of patient characteristics. Determinants that triggered screening (in descending order of popularity) were: tobacco use (N=11), history of cancer (N=10), age >40 (N=7), cancer family history (N=7), age >50 (N=3) and age >60 (N=1). Most respondents indicated preference to order screening tests (in descending order of popularity): mammogram (81%); CT chest & abdomen (78%); myeloma screen (70%); chest x-ray (69%), serum PSA (67%), PAP smear (54%), colonoscope (44%), LDH (41%), pelvic USS (33%), gastroscope (33%), FOBT (33%), tumour markers (28%), CT neck (17%), nuclear bone scan (15%), PET CT (4%) & testicular USS (2%). Respondents (N=57) indicated that cancer screening was problematic due to a lack of clinical practice consensus & guideline (77%), test selection knowledge (37%) and knowledge regarding repeated screening (53%). The potential for harm in conducting screening was identified to be a problem by most respondents (62%).
The practice of malignancy screening in autoimmune myositis amongst Australian Rheumatologists is highly variable. Practice is driven by patient factors and clinician preferences. The cancer screening process is felt on several fronts to have inherent problems. Guideline, consensus and further research is needed in this area to address the challenges and evidence gap. 
